HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Tarsus Pharmaceuticals (NASDAQ:TARS) and increased its price target from $44.00 to $50.00. Tarsus Pharmaceuticals' shares are trading up 7.79% over the last 24 hours, at $19.44 per share. A move to $50.00 would account for a 157.2% increase from the current share price.
July 26, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating for Tarsus Pharmaceuticals and increased its price target, potentially leading to a significant increase in the stock's price.
The maintained Buy rating and increased price target by HC Wainwright & Co. for Tarsus Pharmaceuticals indicates a positive outlook for the company's stock. This could lead to increased investor interest and a potential rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100